Vericel to Host Fourth-Quarter 2014 Earnings Call on March 23, 2015
13 March 2015 - 7:30AM
Vericel Corporation (Nasdaq:VCEL), a leading developer of
patient-specific expanded cellular therapies for the treatment of
severe diseases and conditions, today announced the following
conference call and webcast:
What: |
Vericel, Inc., Fourth Quarter
2014 Earnings Call |
When: |
Monday, March 23, 2015 at
4:30pm (EDT) |
Where: |
http://investors.vcel.com/events.cfm |
How: |
-- The conference call will
be available live in the Investors section of the Vericel website
at http://investors.vcel.com/events.cfm. Please access the site at
least 15 minutes prior to the scheduled start time in order to
download the required audio software if necessary. |
|
-- To participate in the live
call by telephone, please call (877) 312-5881 and reference Vericel
Corporation fourth quarter 2014 investor conference call. If
calling from outside the U.S., please use the international phone
number (253) 237-1173. |
If you are unable to participate during the live call, the
webcast will be available at http://investors.vcel.com/events.cfm
until March 23, 2016. A replay of the call will also be available
until 11:59 pm (EDT) on March 27, 2015 by calling (855) 859-2056,
or from outside the U.S. at (404) 537-3406. The conference ID is
84844964.
About Vericel Corporation
Vericel Corporation (formerly Aastrom Biosciences, Inc.) is a
leader in developing patient-specific expanded cellular therapies
for use in the treatment of patients with severe diseases and
conditions. The company markets two autologous cell therapy
products in the United States: Carticel® (autologous cultured
chondrocytes), an autologous chondrocyte implant for the treatment
of cartilage defects in the knee, and Epicel® (cultured epidermal
autografts), a permanent skin replacement for the treatment of
patients with deep-dermal or full-thickness burns comprising
greater than or equal to 30 percent of total body surface area.
Vericel is also developing MACI™, a third-generation
autologous chondrocyte implant for the treatment of cartilage
defects in the knee, and ixmyelocel-T, a patient-specific
multicellular therapy for the treatment of advanced heart failure
due to ischemic dilated cardiomyopathy. For more information,
please visit the company's website at www.vcel.com.
CONTACT: Chad Rubin
The Trout Group
crubin@troutgroup.com
(646) 378-2947
Or
Lee Stern
The Trout Group
lstern@troutgroup.com
(646) 378-2922
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024